It appears from the lack of feedback on my last post 24 hours...

It appears from the lack of feedback on my last post 24 hours ago that I was not clear enough on the significance of what I tried to convey. So to put it more clearly:

The following ignores the Vitiligo approval and associated market:
Timing of Predicted Market Size	Indication	Market Size (Eligible Procedures)	Comments
Pre FDA June 2023 Soft Tissue Approval	Burns Only	25,000
Pre FDA June 2023 Soft Tissue Approval	FTSD Traumatic Wounds (5 specified types) & FTSD Surgical Wounds (3 specified types)	127,000	This is where Avita got their original 5x market size expansion for soft tissue approval
Post FDA June 2023 Soft Tissue Approval	FTSD Cancer Incision Wounds and Chronic Wounds (4 specified types)	264,000	These additional indications were a"gift" from FDA in its "approved expanded indication of FTSD"
Post FDA June 2023 Soft Tissue Approval	FTSD additional traumatic wounds (gunshot & haematoma).	??	These are also additional indications "gifted" by FDA. No data yet for the market size.
Post FDA June 2023 Soft Tissue Approval	FTSD additional surgical wounds (4 specified types).	??	These are also additional indications "gifted" by FDA. No data yet for the market size.
Post FDA June 2023 Soft Tissue Approval	Additional burns procedures opened up by FTSD approval	10,000	Associated with Level 1 and 2 Trauma Centres.
TOTAL OF ABOVE INDICATIONS:		426,000	This is now >17x the previous burns-only pre-June 23 market. It is likely to be >> 20x once data is available for the other 2 indications above.

This expansion "gift" from FDA increases the burns and soft tissue market available to Avita from 5x to 17 times, and likely >> 20x once more data is available.

As an investor in Avita, I find this highly significant for Avita's valuation.